Response to the Letter to the Editor by Lockley et al. commenting on ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis’

We have read with interest the letter to you from Dr Lockley and colleagues [1] published in response to our manuscript entitled ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis’ that supports surveillance rather than adjuvant chemotherapy in stage I immature teratomas (ITs). This paper was based on the evaluation of the outcomes of 108 patients with pure ITs, as a result of an international collaboration [2].

Lascia un commento